as of 01-28-2026 3:34pm EST
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.4B | IPO Year: | 2017 |
| Target Price: | $60.18 | AVG Volume (30 days): | 499.2K |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.21 - $52.47 | Next Earning Date: | 02-26-2026 |
| Revenue: | $169,467,000 | Revenue Growth: | 196.42% |
| Revenue Growth (this year): | 135.51% | Revenue Growth (next year): | -40.82% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director
Avg Cost/Share
$48.48
Shares
11,000
Total Value
$530,531.29
Owned After
11,640
Chief Medical Officer
Avg Cost/Share
$45.11
Shares
2,235
Total Value
$100,820.85
Owned After
37,213
SEC Form 4
CHIEF LEGAL OFFICER
Avg Cost/Share
$45.96
Shares
9,639
Total Value
$439,199.76
Owned After
16,779
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$45.11
Shares
1,908
Total Value
$86,069.88
Owned After
17,667
SEC Form 4
President, CEO
Avg Cost/Share
$45.11
Shares
9,202
Total Value
$415,102.22
Owned After
466,787
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$43.26
Shares
4,219
Total Value
$182,513.94
Owned After
37,213
SEC Form 4
CHIEF LEGAL OFFICER
Avg Cost/Share
$43.26
Shares
2,983
Total Value
$129,044.58
Owned After
16,779
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$43.26
Shares
3,363
Total Value
$145,483.38
Owned After
17,667
SEC Form 4
President, CEO
Avg Cost/Share
$43.26
Shares
15,309
Total Value
$662,267.34
Owned After
466,787
SEC Form 4
Director
Avg Cost/Share
$49.58
Shares
3,900
Total Value
$193,342.50
Owned After
9,630
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Marquet Magda | ANAB | Director | Jan 15, 2026 | Sell | $48.48 | 11,000 | $530,531.29 | 11,640 | |
| Lizzul Paul F. | ANAB | Chief Medical Officer | Jan 7, 2026 | Sell | $45.11 | 2,235 | $100,820.85 | 37,213 | |
| LOUMEAU ERIC J | ANAB | CHIEF LEGAL OFFICER | Jan 7, 2026 | Sell | $45.96 | 9,639 | $439,199.76 | 16,779 | |
| MULROY DENNIS | ANAB | CHIEF FINANCIAL OFFICER | Jan 7, 2026 | Sell | $45.11 | 1,908 | $86,069.88 | 17,667 | |
| Faga Daniel | ANAB | President, CEO | Jan 7, 2026 | Sell | $45.11 | 9,202 | $415,102.22 | 466,787 | |
| Lizzul Paul F. | ANAB | Chief Medical Officer | Jan 5, 2026 | Sell | $43.26 | 4,219 | $182,513.94 | 37,213 | |
| LOUMEAU ERIC J | ANAB | CHIEF LEGAL OFFICER | Jan 5, 2026 | Sell | $43.26 | 2,983 | $129,044.58 | 16,779 | |
| MULROY DENNIS | ANAB | CHIEF FINANCIAL OFFICER | Jan 5, 2026 | Sell | $43.26 | 3,363 | $145,483.38 | 17,667 | |
| Faga Daniel | ANAB | President, CEO | Jan 5, 2026 | Sell | $43.26 | 15,309 | $662,267.34 | 466,787 | |
| Ware J. Anthony | ANAB | Director | Dec 23, 2025 | Sell | $49.58 | 3,900 | $193,342.50 | 9,630 |
See how ANAB stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ANAB AnaptysBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.